LHNYSEServices-Medical LaboratoriesFiscal year ends December 31
LABCORP HOLDINGS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$318.83+0.88 (+0.28%)
Close on Oct 19, 2026
- Market cap
- $26.14B
- P/E (TTM)
- 26.4
- Dividend yield
- 0.90%
Share price
+$32.89 (+11.50%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
LABCORP HOLDINGS INC. grew revenue 6.4% to $14.35B over the twelve months to Jun 30, 2026. Operating income rose 25.6% to $1.50B, moving the operating margin from 8.8% to 10.4%. Free cash flow was $1.16B, down 8.4% from a year earlier.
Revenue
$14.35B
+6.4% vs. a year earlier
Operating income
$1.50B
+25.6% vs. a year earlier
Free cash flow
$1.16B
-8.4% vs. a year earlier
EPS, diluted
$12.09
+33.3% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $26.14B
- P/E ratio
- 26.4
- Price to sales
- 1.82
- Price to book
- 3.04
- Dividend yield
- 0.90%
- Free cash flow yield
- 4.42%
Fundamentals
- Revenue
- $14.35B
- Net income
- $1.00B
- EPS, diluted
- $12.09
- Free cash flow
- $1.16B
- Book value per share
- $104.96
- Diluted shares
- 82M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$14.35B+6.4% YoY
Gross profit
$4.14B+9.2% YoY
Operating income
$1.50B+25.6% YoY
Net income
$1.00B+31.3% YoY
EPS, diluted
$12.09+33.3% YoY
Free cash flow
$1.16B-8.4% YoY
Reported periodTrailing twelve months